Meanwhile, significantly higher serum C3a (Fig. 5e) and C5a (Fig. 5f) levels were observed in critical, but not mild, COVID-19 patients.39,40 These data collectively indicate that the complement pathways could be aggressively activated in mice infected with Ad-SARS N and critical COVID-19 patients. The gene discussed is C3; the disease is COVID-19.